Cargando…

EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy

The combination of time and order-dependent chemotherapeutic strategies has demonstrated enhanced efficacy in killing cancer cells while minimizing adverse effects. However, the precise mechanism remains elusive. Our results showed that pre-treatment of MCF-7 and MDA-MB-468 cells with epidermal grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yun-Tian, Qian, Xiao-Jun, Yu, Yan, Li, Zhen-Hua, Wu, Rui-Yan, Ji, Jiao, Jiao, Lin, Li, Xuan, Kong, Peng-Fei, Chen, Wen-Dan, Feng, Gong-Kan, Deng, Rong, Zhu, Xiao-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627323/ https://www.ncbi.nlm.nih.gov/pubmed/26036637

Ejemplares similares

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
por: Vouri, M, et al.
Publicado: (2016)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
por: Maruyama, Ichiro N.
Publicado: (2014)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Caspase Cleavage of Receptor Tyrosine Kinases in the Dependence Receptor Family
por: Park, Gyu Hwan, et al.
Publicado: (2023)

Caspase-8 and Tyrosine Kinases: A Dangerous Liaison in Cancer
por: Contadini, Claudia, et al.
Publicado: (2023)

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
por: Han, Weidong, et al.
Publicado: (2011)

Tyrosine kinase c-Abl regulates the survival of plasma cells
por: Li, Yan-Feng, et al.
Publicado: (2017)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

The Role of EGFR/ERK/ELK-1 MAP Kinase Pathway in the Underlying Damage to Diabetic Rat Skin
por: Ge, Xinhong, et al.
Publicado: (2013)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer
por: Luo, Yuan, et al.
Publicado: (2021)

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
por: Zhou, Qing, et al.
Publicado: (2022)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
por: Wang, Fang, et al.
Publicado: (2013)

A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients
por: Liu, Yi, et al.
Publicado: (2011)

Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
por: Qian, Xiao-jun, et al.
Publicado: (2015)

Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
por: Peng, Liang, et al.
Publicado: (2014)

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Li, Xin, et al.
Publicado: (2018)

The Tyrosine Kinase Csk Dimerizes through Its SH3 Domain
por: Levinson, Nicholas M., et al.
Publicado: (2009)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors
por: Yang, Ying, et al.
Publicado: (2022)

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
por: Zhang, Yi-Chen, et al.
Publicado: (2019)

EGFR oligomerization organizes kinase-active dimers into competent signalling platforms
por: Needham, Sarah R., et al.
Publicado: (2016)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients
por: Zhang, Guoqing, et al.
Publicado: (2022)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
por: Li, Dong-Dong, et al.
Publicado: (2013)

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
por: Liu, Yongmei, et al.
Publicado: (2017)

Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liu, Hong-bing, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7js3jja3v5cafmn02mpt1m060s